ES2091916T3 - Metodo para suministrar moleculas en el interior de celulas eucarioticas. - Google Patents

Metodo para suministrar moleculas en el interior de celulas eucarioticas.

Info

Publication number
ES2091916T3
ES2091916T3 ES91903111T ES91903111T ES2091916T3 ES 2091916 T3 ES2091916 T3 ES 2091916T3 ES 91903111 T ES91903111 T ES 91903111T ES 91903111 T ES91903111 T ES 91903111T ES 2091916 T3 ES2091916 T3 ES 2091916T3
Authority
ES
Spain
Prior art keywords
molecules inside
cells
supplying molecules
eucariotic
eucariotic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91903111T
Other languages
English (en)
Inventor
Alan Frankel
Carl Pabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Whitehead Institute for Biomedical Research
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research, Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Whitehead Institute for Biomedical Research
Application granted granted Critical
Publication of ES2091916T3 publication Critical patent/ES2091916T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO PARA EL DESARROLLO DE MOLECULAS EN CELULAS EUCARIOTICAS. UN METODO PARA EL DESARROLLO DE UNA MOLECULA DE INTERES, LA CUAL ES UNA PROTEINA, UN PEPTIDO, UN OLIGONUCLEOTIDO O UN FARMACO, EN LA CELULA, PARTICULARMENTE EN EL NUCLEO DE LA CELULA Y UNA MOLECULA DE CONJUGACION DE PROTEINA DE INTERES TAT QUE ES UTIL EN EL METODO. EL METODO Y LA CONJUGACION SON UTILES PARA PROPOSITOS DE DIAGNOSTICO, PROFILACTICOS Y TERAPEUTICOS.
ES91903111T 1989-12-21 1990-12-21 Metodo para suministrar moleculas en el interior de celulas eucarioticas. Expired - Lifetime ES2091916T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45445089A 1989-12-21 1989-12-21

Publications (1)

Publication Number Publication Date
ES2091916T3 true ES2091916T3 (es) 1996-11-16

Family

ID=23804657

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91903111T Expired - Lifetime ES2091916T3 (es) 1989-12-21 1990-12-21 Metodo para suministrar moleculas en el interior de celulas eucarioticas.

Country Status (10)

Country Link
EP (1) EP0506884B1 (es)
JP (1) JPH05505102A (es)
AT (1) ATE142266T1 (es)
AU (1) AU658818B2 (es)
CA (1) CA2071214C (es)
DE (1) DE69028412T2 (es)
DK (1) DK0506884T3 (es)
ES (1) ES2091916T3 (es)
GR (1) GR3021474T3 (es)
WO (1) WO1991009958A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
NZ239893A (en) * 1990-09-25 1993-11-25 Hoechst Japan A method for introducing a foreign dna into a cell
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
WO1993012234A1 (en) * 1991-12-13 1993-06-24 Sri International Antiviral reagents based on rna-binding proteins
CA2135642C (en) * 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus
ATE420193T1 (de) * 1993-01-26 2009-01-15 Univ Pennsylvania Zusammensetzung zur verabreichung genetischen materials
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
EP0681483B1 (en) 1993-01-26 2005-08-24 The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) Compositions and methods for delivery of genetic material
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
PL337033A1 (en) 1997-05-21 2000-07-31 Univ Leland Stanford Junior Composition for and methods of enhancing transport through permeable biological membranes
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
CA2328457A1 (en) * 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
KR100379578B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법
KR100379577B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
WO2002065986A2 (en) 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties
JP2003009883A (ja) * 2001-07-05 2003-01-14 Mitsubishi Pharma Corp マスト細胞の細胞死誘発剤
KR100495138B1 (ko) * 2001-07-31 2005-06-14 학교법인 한림대학교 식물세포 투과 도메인-화물분자 복합체
DE10212867B4 (de) * 2002-03-22 2005-07-21 Hans Prof. Dr. Wolf Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie
KR100472939B1 (ko) * 2002-05-24 2005-03-18 학교법인 한림대학교 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도
CA2493674A1 (en) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimers as molecular translocators
KR100472937B1 (ko) * 2002-07-25 2005-03-10 학교법인 한림대학교 세포침투성 티에이티-사이토신 디아미네이즈 융합단백질및 그 용도
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
WO2006094200A2 (en) * 2005-03-03 2006-09-08 The Trustees Of Boston College Method of obtaining a desired localization for cellular imaging with the use of peptidoconjugates
US7935816B2 (en) 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
JP6124791B2 (ja) * 2010-09-22 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Ｓｍａｄ７の治療的適用
WO2014138670A1 (en) 2013-03-08 2014-09-12 The Regents Of The University Of Colorado, A Body Corporate Ptd-smad7 therapeutics
KR101835554B1 (ko) 2014-06-24 2018-04-19 서울대학교 산학협력단 C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
JP7495230B2 (ja) 2017-04-28 2024-06-04 オークランド ユニサービシズ リミテッド 処置方法および新規構築物
US20210046153A1 (en) * 2018-05-03 2021-02-18 University Of Utah Research Foundation Oca-b peptide conjugates and methods of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
EP0273085A1 (en) * 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates

Also Published As

Publication number Publication date
EP0506884B1 (en) 1996-09-04
JPH05505102A (ja) 1993-08-05
WO1991009958A2 (en) 1991-07-11
DE69028412D1 (de) 1996-10-10
DE69028412T2 (de) 1997-03-27
WO1991009958A3 (en) 1991-08-08
GR3021474T3 (en) 1997-01-31
ATE142266T1 (de) 1996-09-15
EP0506884A1 (en) 1992-10-07
AU7182991A (en) 1991-07-24
AU658818B2 (en) 1995-05-04
CA2071214A1 (en) 1991-06-22
DK0506884T3 (da) 1996-11-04
CA2071214C (en) 2006-06-06

Similar Documents

Publication Publication Date Title
ES2091916T3 (es) Metodo para suministrar moleculas en el interior de celulas eucarioticas.
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
DE69938867D1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
AU1926899A (en) Exploiting genomics in the search for new drugs
DE69621953T2 (de) Vehikel zum einbringen von nukleinsäuren in zellen
DE69123981D1 (de) Nützliche retrovirale vektoren für die gentherapie
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
NO993764L (no) Elektrokjemiske prober for deteksjon av molekylære interaksjoner og legemiddeloppdagelse
DE69025089D1 (de) Elektrochemische Zellen
DK1115874T3 (da) Alzheimer's sygdom-sekretase
DK0719340T3 (da) Klonet glutaminsyre-decarboxylase
EP1032705A4 (en) PROBE ARRANGEMENTS AND THEIR USES FOR METHODS FOR DNA DISTINCTION
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
HUP0301812A2 (hu) Átvizsgálási (screening) eljárás
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DK1082423T3 (da) Cyclin E2-gener og -proteiner
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
DE69725754D1 (de) Eingekapselte Antikörper-produzierende Zellen
GB9718952D0 (en) Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
DE69728897D1 (de) Saeugetierchemokine
EA199800959A1 (ru) ПРИМЕНЕНИЕ ГЕНЕТИЧЕСКОЙ МОДИФИКАЦИИ В ГЕНЕ b3- СУБЪЕДИНИЦЫ ЧЕЛОВЕЧЕСКОГО G-ПРОТЕИНА ДЛЯ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ
ATE218620T1 (de) Verfahren zur erkennung von malignen transformierten menschlichen zellen
ES2045004T3 (es) Procedimiento para la preparacion de proteinas extra\as en estreptomicetos.
EP0372862A3 (en) Cyclosporine binding protein and its use in an assay for biologically-active cyclosporine
DE69735760D1 (de) Antikörper gegen menschliches lect2, zellen die diesen produzieren und verfahren und kit zu dessen bestimmung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506884

Country of ref document: ES